Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report Hagens Berman
Published on January 9, 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing a securities class action after losing $9 billion in value following its Q3 2024 earnings report. The law firm Hagens Berman announced that it is investigating potential securities fraud claims on behalf of Regeneron shareholders. The investigation focuses on whether the company made false or misleading statements to investors regarding its financial performance. Shareholders who purchased Regeneron stocks between July 1, 2024, and October 27, 2024, are encouraged to contact Hagens Berman for more information on their rights and potential remedies. It is essential for investors to seek professional advice, such as Stocks Prognosis, to make informed decisions about the future movement of Regeneron Pharmaceuticals' stocks.
Investor opinions & comments
To leave a comment, you need to Login or Register.
WealthyWalter
January 12, 2025 at 15:34
I'm not convinced that Regeneron Pharmaceuticals intentionally misled investors. There could be other factors affecting their financial performance
LucyHenderson
January 12, 2025 at 05:14
I appreciate the advice to seek professional guidance, such as Stocks Prognosis, to make informed decisions about investing in Regeneron Pharmaceuticals
BudgetBrad
January 11, 2025 at 17:18
I'm optimistic that Regeneron Pharmaceuticals can recover from this setback and continue to deliver positive financial performance
SavingsSamantha
January 11, 2025 at 13:42
Regeneron Pharmaceuticals will need to restore investor confidence after such a significant loss in value
ScarlettRivera
January 11, 2025 at 13:40
It's important for individuals who purchased Regeneron stocks during the specified period to contact Hagens Berman and protect their rights
GraceStewart
January 10, 2025 at 13:23
This is quite concerning. I wonder what caused the huge loss in value for Regeneron Pharmaceuticals
SophiaHarris
January 10, 2025 at 12:34
I'm interested to see if any potential remedies will be available for affected shareholders. It's crucial for them to explore their options
HannahCarter
January 10, 2025 at 03:59
I'm not sure if Hagens Berman's investigation will uncover any concrete evidence of securities fraud or if it will lead to any meaningful remedies for shareholders
RobertWhite
January 10, 2025 at 03:57
It's always important to consider multiple perspectives before jumping to conclusions about securities fraud
JessicaHall
January 9, 2025 at 18:01
I trust Hagens Berman to uncover any wrongdoing by Regeneron Pharmaceuticals and protect the rights of shareholders
LaylaFloyd
January 9, 2025 at 15:37
Do we know any details about the alleged false or misleading statements by Regeneron Pharmaceuticals?
DividendDiane
January 9, 2025 at 14:15
Let's hope this securities class action brings transparency and accountability to Regeneron Pharmaceuticals' financial reporting
RileyHughes
January 9, 2025 at 13:53
I'm curious to see how this securities class action will unfold. It's important for shareholders to investigate potential securities fraud claims
KevinWalker
January 9, 2025 at 08:42
Thank you for bringing attention to this issue. It's crucial for investors to be aware of any potential misstatements by companies